A systematic review of the comparative safety of colloids

被引:142
作者
Barron, ME
Wilkes, MM
Navickis, RJ
机构
[1] Hygeia Associates, Grass Valley, CA 95949 USA
[2] Univ Miami, Sch Med, Dept Anesthesiol, Coral Gables, FL 33124 USA
[3] Amer Red Cross, Washington, DC 20006 USA
关键词
D O I
10.1001/archsurg.139.5.552
中图分类号
R61 [外科手术学];
学科分类号
摘要
Hypothesis: Safety differences exist among colloids widely used for fluid management in acutely ill patients, as judged according to the comparative incidence of adverse events. Data Sources: Colloid safety data for human subjects were sought, without language or time period restrictions, by means of computer searches of bibliographic and clinical trial databases, hand searches of medical journals and Index Medicus, inquiries with investigators and colloid suppliers, and examination of reference lists. Search terms included "colloids", "morbidity", and "mortality". Study Selection: Controlled trials, cohort studies, phar-macovigilance studies, and prior meta-analyses were independently selected by 2 unblinded investigators. Of 189 candidate studies, 113 were included, with safety data encompassing 1.54 X 10(6) patients and 1.09 X 10(8) colloid infusions. Data Extraction: Two unblinded investigators independently extracted data. Study limitations and confounding factors were tabulated. Data Synthesis: With albumin as the reference colloid, the incidence rate ratio for anaphylactoid reactions was 4.51 (95% confidence interval, 2.06-9.89) after hy-droxyethyl starch administration, 2.32 (95% confidence interval, 1.21-4.45) after dextran, and 12.4 (95% confidence interval, 6.40-24.0) after gelatin. Pruritus occurrence was significantly increased by hydroxyethyl starch exposure (odds ratio, 1.78-1 95% confidence interval, 1.23-2.58). Artificial colloid administration was consistently associated with coagulopathy and clinical bleeding, most frequently in cardiac surgery patients receiving hydroxyethyl starch. On the basis of large-scale pharma-covigilance study results, albumin infusion resulted in a low rate of both total adverse events (3.1 to 8.6 per 10(5) infusions) and serious adverse events (1.29 per 10(6) infusions). Conclusions: Significant safety differences exist among colloids. Therefore, conclusions regarding the clinical usefulness of colloids as a fluid class should be formed with caution.
引用
收藏
页码:552 / 563
页数:12
相关论文
共 117 条
[1]  
ALBEGGER K, 1992, WIEN MED WOCHENSCHR, V142, P1
[2]   Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis [J].
Altman, C ;
Bernard, B ;
Roulot, D ;
Vitte, RL ;
Ink, O .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1998, 10 (01) :5-10
[3]  
[Anonymous], J ANAESTH CLIN PHARM
[4]   DEXTRAN DEPOSITS IN TISSUES OF PATIENTS UNDERGOING HEMODIALYSIS [J].
BERGONZI, G ;
PATIES, C ;
VASSALLO, G ;
ZANGRANDI, A ;
POISETTI, PG ;
BALLOCCHI, S ;
FONTANA, F ;
SCARPIONI, L .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1990, 5 (01) :54-58
[5]   Hydroxyethylstarch and osmotic nephrosis-like lesions in kidney transplants [J].
Bernard, C ;
Alain, M ;
Simone, C ;
Xavier, M ;
JeanFrancois, M .
LANCET, 1996, 348 (9041) :1595-1595
[6]   Incidence of acute oligoanuric renal failure in dextran 40 treated patients with acute ischemic stroke stage III or IV [J].
Biesenbach, G ;
Kaiser, W ;
Zazgornik, J .
RENAL FAILURE, 1997, 19 (01) :69-75
[7]  
BLANLOEIL Y, 1983, THERAPIE, V38, P539
[8]   INFLUENCE OF DIFFERENT INTRAVASCULAR VOLUME THERAPIES ON PLATELET-FUNCTION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS [J].
BOLDT, J ;
KNOTHE, C ;
ZICKMANN, B ;
ANDRES, P ;
DAPPER, F ;
HEMPELMANN, G .
ANESTHESIA AND ANALGESIA, 1993, 76 (06) :1185-1190
[9]   RETRACTED: VOLUME REPLACEMENT WITH HYDROXYETHYL STARCH SOLUTION IN CHILDREN (Retracted article. See vol. 125, pg. 413, 2020) [J].
BOLDT, J ;
KNOTHE, C ;
SCHINDLER, E ;
HAMMERMANN, H ;
DAPPER, F ;
HEMPELMANN, G .
BRITISH JOURNAL OF ANAESTHESIA, 1993, 70 (06) :661-665
[10]  
BOLDT J, 1986, INFUS KLIN ERN, V13, P145